

●► **Eli Lilly and Company**

*(FDA, Approval)*

The US FDA has approved Lilly's OMVOH for the treatment of Crohn's disease

---

●► **Amgen**

*(FDA, Approval)*

Amgen announced that the FDA had approved a combination of Lumakras® (sotorasib) and Vectibix® (panitumumab) for the treatment of chemoresistant KRAS G12C-mutated metastatic colorectal cancer

---

●► **Incyte + Syndax**

*(FDA, Approval)*

Incyte and Syndax received FDA approval for NIKTIMVO (9 mg and 22 mg vial sizes) used in the treatment of chronic GVHD

---

●► **IMPACT Therapeutics**

*(NMPA, Approval)*

NMPA grants approval for IMPACT Therapeutics' senaparib as first-line maintenance therapy in ovarian cancer

---

●► **UCB**

*(US, Launches)*

UCB has launched a 320 mg/2 mL single-injection option for BIMZELX in the US market



●▶ **Spinogenix**

*(FDA, FTD)*

The FDA has granted FTD to Spinogenix's SPG601 for the treatment of fragile X syndrome, a common inherited form of autism

---

●▶ **Innovent**

*(NMPA, BTD)*

NMPA has granted BTD to Innovent's IBI343 as a monotherapy for advanced pancreatic cancer

---

●▶ **Ginkgo Bioworks**

*(Partnership)*

Ginkgo Bioworks collaborated with Universal Cells (an Astellas company) towards building next-generation induced pluripotent stem cells (iPSC)-derived cancer cell therapies targeting solid tumors

---

●▶ **Synthego + AstraZeneca**

*(Agreement)*

Synthego has entered into a strategic licensing agreement with AstraZeneca to grant a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON

---

●▶ **Eli Lilly and Company**

*(Acquisition)*

Lilly acquires Scorpion Therapeutics' PI3K $\alpha$  inhibitor program STX-478 in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors



●▶ **AbbVie + Simcere Zaiming**

*(Partnership)*

AbbVie + Simcere Zaiming have collaborated to develop a novel tri-specific antibody candidate for multiple myeloma

---

●▶ **REGENXBIO + Nippon Shinyaku**

*(Partnership)*

REGENXBIO + Nippon Shinyaku have partnered to develop and commercialize RGX-121 and RGX-111 for MPS diseases

---

●▶ **Hikma + Emergent BioSolutions**

*(Partnership)*

Hikma announced an exclusive commercial partnership with Emergent BioSolutions for KLOXXADO (naloxone HCl) nasal spray 8 mg used for the treatment of opioid overdose

---

●▶ **Caris Life Sciences + Ontada**

*(Partnership)*

Caris Life Sciences partners with Ontada to enhance oncology research and promote precision medicine adoption

